Stabilization and regression of albuminuria in Chinese patients with type 2 diabetes: A one-year randomized study of valsartan versus enalapril

Advances in Therapy

Volumn 22, Issue 2, 2005, Pages 155-162

  Ko, Gary T C ^a   Tsang, Chiu Chi ^a   Chan, Hamish C K ^a  

^a ALICE HO MIU LING NETHERSOLE HOSPITAL   (Hong Kong)

Author keywords

Albuminuria; Chinese; Diabetic nephropathy; Enalapril; Type 2 diabetes; Valsartan

Indexed keywords

ALBUMIN; CREATININE; ENALAPRIL; POTASSIUM; VALSARTAN;

ADULT; AGED; ARTHRALGIA; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CHINESE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DEMOGRAPHY; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FINGER; HEART PALPITATION; HUMAN; KIDNEY FUNCTION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PARESTHESIA; POTASSIUM BLOOD LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REMISSION; SHORT COURSE THERAPY; STROKE; URINALYSIS;

EID: 21044445649     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02849886     Document Type: Article

References (27)

1. Ritz E, Tarng DC. Renal disease in type 2 diabetes. Nephrol Dial Transplant. 2001;16(suppl 5):11-18.
2. Lui SF. Chronic renal failure. In: Sung JY, Li PK, Sanderson JE, Woo J, eds. Textbook of Clinical Medicine for Asia. Hong Kong: The Chinese University Press; 1998:311-318.
3. Parving HH, Oxenboll B, Svendsen PA, et al. Early detection of patients at risk of developing diabetic nephropathy: a longitudinal study of urinary albumin excretion. Acta Endocrinol. 1982; 100:550-555.
4. Tuttle KR, Stein JH, De Fronzo RA. The natural history of diabetic nephropathy. Semin Nephrol. 1990;10:184-193.
5. Mathiesen E, Ronn B, Jensen T, et al. Relationship between blood pressure and urinary albumin excretion in development of microalbuminuria. Diabetes. 1990;39:245-249.
6. Ritz E. Hypertension in diabetic nephropathy: prevention and treatment. Am Heart J. 1993;125: 1514-1519.
7. Ruilope LM, Luno J. Angiotensin blockade in type 2 diabetic renal disease. Kidney Int Suppl. 2002;82:61-63.
8. Deferrari G, Ravera M, Berruti V. Treatment of diabetic nephropathy in its early stages. Diabetes Metab Res Rev. 2003;19:101-114.
9. Yeung VT, Chan SH, Cheng KK, on behalf of MAPS investigators. Microalbuminuria Prevalence Study (MAPS) in hypertensive type 2 diabetic patients in Asia: Hong Kong data. The 5th Hong Kong Diabetes and Cardiovascular Risk Factors East-Meets-West Symposium, 2003. Abstract A0026.
10. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: a systematic overview of the literature. Arch Intern Med. 1997;157: 1413-1418.
11. Weinstock BW, Keane WF. Proteinuria and cardiovascular disease. Am J Kidney Dis. 2001; 38(suppl 1):S8-S13.
12. Hostetter TH. Mechanisms of diabetic nephropathy. Am J Kidney Dis. 1994;23:188-192.
13. Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Int Med. 1993;118:129-138.
14. Chan JC, Ko GT, Leung D, et al. The long term effects of angiotensin converting enzyme inhibition and metabolic control on cardiovascular and renal outcomes in hypertensive type 2 diabetic patients. Kidney Int. 2000;57:590-600.
15. Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation. 1998;97:1411-1420.
16. Berl T. Angiotensin-converting enzyme inhibitors versus AT1 receptor antagonist in cardiovascular and renal protection: the case for AT1 receptor antagonist. J Am Soc Nephrol. 2004;15(suppl 1): S71-S76.
17. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P, and the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345: 870-878.
18. Brenner BM, Cooper ME, de Zeeuw D, et al, and the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
19. Lewis EJ, Hunsicker LG, Clarke WR, et al, and the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
20. Viberti G, Wheeldon NM, for the Microalbuminuria Reduction With Valsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes: a blood pressure-independent effect. Circulation. 2002;106:672-678.
21. Taal MW, Brenner BM. Combination ACEI and ARB therapy: additional benefit in renoprotection? Curr Opin Nephrol Hypertens. 2002;11:377-381.
22. Ferrari P, Marti HP, Pfister M, Frey FJ. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. J Hypertens. 2002;20:125-130.
23. Lacourciere Y, Belanger A, Godin C, et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int. 2000;58: 762-769.
24. Barnett AH, Bain SC, Bouter P, et al, and the Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351:1952-1961.
25. Chan JC, Cockram CS, Nicholls MG, Cheung CK, Swaminathan R. Comparison of enalapril and nifedipine in treating NTDDM associated with hypertension: one year analysis. BMJ. 1992; 305:981-985.
26. Kumagai H, Sakata K, Matsuura T, et al. Comparison of ARB and ACEI for renoprotection in chronic glomerulonephritis [in Japanese]. Nippon Rinsho. 2002;60:2005-2013.
27. Matsuda H, Hayashi K, Homma K, et al. Differing anti-proteinuric action of candesartan and losartan in chronic renal disease. Hypertens Res. 2003;26:875-880.